In this recent webinar, experts John Neal, Katya Svoboda, and David Byram examine the major policy shifts transforming the U.S. drug pricing landscape—including the accelerating impact of MFN models, evolving MFPs, PBM transparency reforms, and the growth of direct-to-patient models.
The discussion highlights how these policies intersect, the risks and opportunities they create for manufacturers, and the strategic implications that market access teams should consider as they prepare for 2026 and beyond.
Have questions about how MFN, evolving MFPs, and PBM reforms could affect your brand?
Meet with EVERSANA for a 30‑minute discussion to assess implications and potential paths forward.
Complete the form to access the full recording and learn how policy stacking is reshaping pricing, access, and market dynamics.
Author
David brings 34 years of pharmaceutical, biotechnology, device, and diagnostic industry leadership experience in commercialization, market access, reimbursement, HEOR, government affairs, sales, and marketing. Currently, David co-leads the EVERSANA U.S. Pricing and Market Access…
John brings over 30 of pharmaceutical, biotechnology, device, and diagnostic industry leadership experience in commercialization, market access, reimbursement, HEOR, government affairs, sales, and marketing. John has an extensive background in life sciences management consulting focused…
Katya comes to EVERSANA Management Consulting from ICON, where she was Senior Principal/Interim Divisional Principal, Global Pricing and Market Access. In this role, Katya worked across teams on client engagements, internal initiatives, business development,…